https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43531 Wed 21 Sep 2022 11:32:29 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47143 Wed 14 Dec 2022 15:27:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16753 Wed 11 Apr 2018 15:29:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51626 Tue 12 Sep 2023 15:40:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46465 n=388) and CHHiP (n=241) trials onto the same exemplar and repeating the tests on each of these data sets, and on all three datasets combined. Results: Voxel-based Cox regression and permutation dose difference testing revealed regions where increased dose was correlated with gastrointestinal toxicity. Grade=2 RB was associated with posteriorly extended lateral beams that manifested high doses (> 55 Gy) in a small rectal volume adjacent to the clinical target volume. A correlation was found between grade=2 tenesmus and increased low-intermediate dose (~25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS). Conclusions: The serial response of the rectum with respect to RB has been demonstrated in patients with posteriorly extended lateral beams. Similarly, the parallel response of the PRFS with respect to tenesmus has been demonstrated in patients treated with the posterior beam.]]> Thu 24 Nov 2022 15:46:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42975 Thu 22 Jun 2023 08:51:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40019 n = 388) and CHHiP (up to n = 247) trials onto the same exemplar and repeating the voxel-based tests on each of these data sets. All three datasets were then combined, and the tests repeated. Results: Voxel-based Cox regression and multiple comparison permutation dose difference testing revealed regions where increased dose was correlated with genitourinary toxicity. Increased dose in the vicinity of the membranous and spongy urethra was associated with dysuria for all datasets. Haematuria was similarly correlated with increased dose at the membranous and spongy urethra, for the RADAR, CHHiP, and combined datasets. Some evidence was found for the association between incontinence and increased dose at the internal and external urethral sphincter for RADAR and the internal sphincter alone for the combined dataset. Incontinence was also strongly correlated with dose from posterior oblique beams. Patients with fields extending inferiorly and posteriorly to the CTV, adjacent to the membranous and spongy urethra, were found to experience increased frequency. Conclusions: Anatomically-localized dose-toxicity relationships were determined for late genitourinary symptoms in the urethra and urinary sphincters. Low-intermediate doses to the extraprostatic urethra were associated with risk of late dysuria and haematuria, while dose to the urinary sphincters was associated with incontinence.]]> Thu 14 Jul 2022 13:55:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7330 Sat 24 Mar 2018 08:35:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18210 Sat 24 Mar 2018 08:04:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21106 Sat 24 Mar 2018 07:53:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:239 Sat 24 Mar 2018 07:42:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26274 Sat 24 Mar 2018 07:40:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26791 Sat 24 Mar 2018 07:36:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:3423 Sat 24 Mar 2018 07:21:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22835 1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions: The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.]]> Sat 24 Mar 2018 07:16:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33247 7 cutpoint identified in 2014 for the BP and STI endpoints. A tertiary objective of the trial is to determine whether intercurrent medical conditions will impact independently on delayed radiotherapy morbidity and other treatment related morbidity.]]> Mon 23 Sep 2019 13:37:53 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48542 Mon 08 May 2023 15:40:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42619 Mon 04 Sep 2023 13:58:46 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33735 Fri 14 Dec 2018 14:41:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38069 Fri 12 Nov 2021 12:17:35 AEDT ]]>